Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2013

Open Access 01-12-2013 | Research article

Prevalence and determinants of controlled hypertension in a German population cohort

Authors: Neeltje van den Berg, Claudia Meinke-Franze, Thomas Fiss, Sebastian E Baumeister, Wolfgang Hoffmann

Published in: BMC Public Health | Issue 1/2013

Login to get access

Abstract

Background

Data of the German population-based cohort SHIP (Study of Health in Pomerania) were analysed to examine treatment rates, antihypertensive substances prescribed, and the proportion of hypertensive study participants reaching target values for blood pressure as well as determinants.

Methods

The study population was defined using baseline data of the cohort (collected between 1997 and 2001). Participants with blood pressure values ≥140/90 mmHg and/or antihypertensive medication with known hypertension and participants with risk-comorbidity (diabetes, stroke, angina pectoris, and/or myocardial infarction) and blood pressure values ≥130/80 mmHg were included. The analysis of treatment and target values was based on the 5-year follow-up of the cohort (collected between 2002 and 2006). Logistic regression was used to identify determinants for a normotensive blood pressure.

Results

3278 SHIP-participants with hypertensive blood pressure values were included (mean age: 55.5 years; SD 13.6, range 21–80 years). The raw hypertension prevalence was 50.9% (N = 1761). 58.7% (N = 1074) of all hypertensive patients reported some form of antihypertensive treatment. Thereof 65.1% (N = 728) received combination therapy. Of the patients without risk-comorbidity, 42.1% (N = 489) reached their target blood pressure values at the time of the 5-year follow-up of the cohort. Of the patients with any risk-comorbidity this proportion was only 21.7% (N = 131). Significant determinants for reaching the target values were being female and having antihypertensive combination therapy. Increasing age, having risk-comorbidities, and obesity were negatively associated with reaching the target values.

Conclusions

Both the proportion of participants receiving therapy and the number of participants reaching their target blood pressure values are very low. Combination therapy is associated with better blood pressure control as compared to mono therapy. However, even in the subgroup of hypertensive patients under combination therapy only 36% (both patients with and without comorbidity) reach target values.
Appendix
Available only for authorised users
Literature
1.
Meisinger C, Heier M, Völzke H, Löwel H, Mitusch R, Hense HW, Lüdemann J: Regional disparities of hypertension prevalence and management within Germany. J Hypertens. 2006, 24 (2): 293-299. 10.1097/01.hjh.0000200508.10324.8e.CrossRefPubMed
2.
Löwel H, Meisinger C, Heier M, Hymer H, Alte D, Völzke H: Epidemiology of hypertension in Germany. Selected results of population-representative cross-sectional studies. Dtsch Med Wochenschr. 2006, 131 (46): 2586-2591. 10.1055/s-2006-956253.CrossRefPubMed
3.
Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodríguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003, 289 (18): 2363-2369. 10.1001/jama.289.18.2363.CrossRefPubMed
4.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: analysis of worldwide data. Lancet. 2005, 365: 217-223.CrossRefPubMed
5.
Janhsen K, Strube H, Starker A: Gesundheitsberichterstattung des Bundes - Heft 43: Hypertonie. 2008, Berlin: Oktoberdruck AG
6.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology, et al: 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007, 25 (6): 1105-1187. 10.1097/HJH.0b013e3281fc975a.CrossRefPubMed
7.
8.
Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, European Society of Hypertension, et al: Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. J Hypertens. 2009, 27 (11): 2121-2158. 10.1097/HJH.0b013e328333146d.CrossRefPubMed
9.
10.
Rahn KH: Differential hypertensive therapy according to the guidelines. Internist. 2009, 50: 433-441. 10.1007/s00108-008-2292-8.CrossRefPubMed
11.
John U, Greiner B, Hensel E, Lüdemann J, Piek M, Sauer S, Adam C, Born G, Alte D, Greiser E, Haertel U, Hense HW, Haerting J, Willich S, Kessler C: Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz Praventivmed. 2001, 46 (3): 186-194. 10.1007/BF01324255.CrossRefPubMed
12.
Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G, Havemann C, Ittermann T, Schipf S, Haring R, Baumeister SE, Wallaschofski H, Nauck M, Frick S, Arnold A, Jünger M, Mayerle J, Kraft M, Lerch MM, Dörr M, Reffelmann T, Empen K, Felix SB, Obst A, Koch B, Gläser S, et al: Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011, 40 (2): 294-307. 10.1093/ije/dyp394.CrossRefPubMed
13.
Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen: Amtliche Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahr 2006. 2008, Köln: DIMDI
14.
7.Guidelines Sub-Committee: 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens. 1999, 17: 151-183.
15.
Fiss T, Ritter CA, Alte D, van den Berg N, Hoffmann W: Detection of drug related problems in an interdisciplinary health care model for rural areas in Germany. Pharm World Sci. 2010, 32 (5): 566-574. 10.1007/s11096-010-9409-6.CrossRefPubMed
16.
McAlister FA, Wilkins K, Joffres M, Leenen FH, Fodor G, Gee M, Tremblay MS, Walker R, Johansen H, Campbell N: Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ. 2011, 183 (9): 1007-1013. 10.1503/cmaj.101767.CrossRefPubMedPubMedCentral
17.
Erkens JA, Panneman MM, Klungel OH, van den Boom G, Prescott MF, Herings RM: Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf. 2005, 14 (11): 795-803. 10.1002/pds.1156.CrossRefPubMed
18.
Turner BJ, Hollenbeak C, Weiner MG, Ten Have T, Roberts C: Barriers to adherence and hypertension control in a racially diverse representative sample of elderly primary care patients. Pharmacoepidemiol Drug Saf. 2009, 18 (8): 672-681. 10.1002/pds.1766.CrossRefPubMed
19.
Borzecki AM, Oliveria SA, Berlowitz DR: Barriers to hypertension control. Am Heart J. 2005, 149 (5): 785-794. 10.1016/j.ahj.2005.01.047.CrossRefPubMed
20.
Schaefer M: Discussing basic principles for a coding system of drug-related problems: the case of PI-Doc. Pharm World Sci. 2002, 24 (4): 120-127. 10.1023/A:1019543029936.CrossRefPubMed
Metadata
Title
Prevalence and determinants of controlled hypertension in a German population cohort
Authors
Neeltje van den Berg
Claudia Meinke-Franze
Thomas Fiss
Sebastian E Baumeister
Wolfgang Hoffmann
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2013
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-13-594

Other articles of this Issue 1/2013

BMC Public Health 1/2013 Go to the issue

Research article

Health system delay in pulmonary tuberculosis treatment in a country with an intermediate burden of tuberculosis: a cross-sectional study

Research article

Determinants and protective behaviours regarding tick bites among school children in the Netherlands: a cross-sectional study

Research article

Canadian national surveys on pandemic influenza preparations: pre-pandemic and peri-pandemic findings

Study protocol

Improving mental health of adolescents with Type 1 diabetes: protocol for a randomized controlled trial of the Nothing Ventured Nothing Gained online adolescent and parenting support intervention

Research article

A sero-survey of toxoplasmosis in farm and non-farm children from Wisconsin, United States, 1997–1999

Research article

Local level epidemiological analysis of TB in people from a high incidence country of birth